• About
  • Services
  • Clients
  • Client News
  • PCG Research
  • PCG Digital
  • Contact
  • follow:

  • 22 Jun

    Lexaria’s Groundbreaking Research into DehydraTECH-CBD Published in International Journal of Molecular Science

    DehydraTECH-CBD now featured in eight published, peer-reviewed papers KELOWNA, BC / ACCESSWIRE / June 22, 2023 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that its groundbreaking research utilizing DehydraTECH-processed cannabidiol ("DehydraTECH-CBD") has now been published in eight peer-reviewed articles in… Read More..

    Share this:
  • 22 Jun

    NextCure Presents Non-Clinical Data Defining the Mechanism of NC525 at the 2023 Federation of Clinical Immunology Societies (FOCIS) Annual Meeting

    BELTSVILLE, Md., June 21, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the presentation of a poster that defines the mechanism of NC525-induced apoptosis of leukemic cells, but not healthy… Read More..

    Share this:
  • 20 Jun

    Timber Pharmaceuticals to Present Interim Analyses From Phase 3 ASCEND Study of TMB-001 in Congenital Ichthyosis

    - First Presentation of Data From Phase 3 ASCEND Study Will Feature Pharmacokinetic Results That Indicate Minimal Systemic Absorption of Isotretinoin - - Data to be Presented at the Society for Pediatric Dermatology’s Annual Meeting - WARREN, NJ, June 20, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc.… Read More..

    Share this:
« Previous 1 … 140 141 142 143 144 … 235 Next »
  • Twitter feed is not available at the moment.
  • QUICK LINKS

    • About
    • Services
    • Clients
    • Client Media
    • PCG Media
    • PCG Research
    • Contact
    • Privacy Policy
    • Disclosures

    FOLLOW US

    Copyright © 2022 PCG Advisory.

    MENU logo
    • About
    • Services
    • Clients
    • Client News
    • PCG Research
    • PCG Digital
    • Contact